It's amazing how the markets always find an excuse as to why a name like ADMP can't gain any traction.
I remember that their insulin sales where going to drive the pps higher...but, but, but
I remember when Zimhi getting FDA approved was a game changer and would send ADMP's pps up like a rocket...but, but, but
I remember when Tempol was going to be the holy grail of Covid treatment but can barely get enough ppl in a study (200) even though cases are rising. Can't even get an emergency designation for such a 'safe' drug...but, but, but
I think I will ignore the markets on this one. They suck.